Lifevantage Corp. 10-Q Summary: Quarter Ended September 30, 2024
Business Context and Reporting Period
This report covers the three-month period ended September 30, 2024 (Q1 of Fiscal 2025). Lifevantage Corporation is a nutrigenomics company selling dietary supplements, skin care, and nootropic products through a direct sales network of independent consultants. The company operates in the Americas and Asia/Pacific & Europe regions.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net Revenue | $47.2 million | $51.4 million |
| Gross Profit | $37.7 million (79.9% margin) | $41.2 million (80.2% margin) |
| Operating Income | $2.6 million | $0.7 million |
| Net Income | $1.8 million ($0.15 basic EPS) | $0.6 million ($0.05 basic EPS) |
| Cash and Equivalents | $14.6 million | $18.4 million |
| Working Capital | $16.7 million | N/A |
| Debt Outstanding | $0 (Credit facility unused) | N/A |
Liquidity: The company reported a net cash outflow from operating activities of $0.6 million, compared to an inflow of $4.8 million in the prior year. Financing activities used $1.8 million, primarily for dividends ($0.5 million) and share repurchases ($1.1 million).
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 8.1% year-over-year. The Americas region declined 4.2%, while the Asia/Pacific & Europe region dropped 19.7%, driven by a 20.5% decrease in active accounts and foreign currency headwinds (specifically in Japan).
- Profitability Improvement: Despite lower revenue, Net Income increased 190% to $1.8 million. This was driven by a significant reduction in Selling, General, and Administrative (SG&A) expenses, which fell 17.3% year-over-year due to the termination of a sports endorsement agreement and reduced proxy contest expenses.
- Account Base Contraction: Total active accounts (consultants and customers) decreased 10.2% to 123,000. Active independent consultants fell 9.6% to 47,000.
- Product Mix: Revenue from the TrueScience Liquid Collagen product declined slightly in the Americas and significantly in Japan.
Outlook, Risks, and Management Commentary
- Product Launches: The company launched the "MindBody GLP-1 System" in the U.S. in October 2024 and continues to refine its product lineup internationally to drive average order size.
- Capital Allocation: The company continues its share repurchase program, with $19.3 million remaining under the $60 million authorization. A quarterly dividend of $0.04 per share was paid.
- Debt Facility: A $5.0 million revolving credit facility with Bank of America was established in April 2024. As of September 30, 2024, no amounts were drawn, and the company is in compliance with all covenants.
- Risks: Key risks include the ability to retain independent consultants, dependence on a few key products, foreign currency fluctuations, and potential regulatory actions regarding direct selling models. The company also notes risks related to cybersecurity and data privacy.
Investor Verification Checklist
- Verify the sustainability of SG&A expense reductions, specifically the one-time nature of the proxy contest and endorsement termination savings.
- Monitor the trend in "Active Accounts" and "Active Independent Consultants" to assess the health of the direct sales network.
- Review the impact of foreign currency exchange rates on the Asia/Pacific & Europe region, particularly the Japanese Yen.
- Assess the performance of new product launches (MindBody GLP-1 System) in upcoming quarters to offset declines in legacy products like Liquid Collagen.
- Confirm the company's ability to maintain liquidity given the shift from positive to negative operating cash flow in the quarter.